SUZHOU, China and ROCKVILLE, Md., May 16, 2024 PRNewswire -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and age-related diseases, announced today that the latest results from five studies have been selected for Poster Presentations at the 2024 European Hematology Association Hybrid Congress .
About Ascentage PharmaAscentage Pharma is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
2024 Results From Five Studies Of Ascentage Pharma's Key Drug Candidates Selected For Presentations At 2024 European Hematology Association Hybrid Congress
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TheManilaTimes - 🏆 2. / 92 Read more »
Source: MlaStandard - 🏆 20. / 55 Read more »
Source: MlaStandard - 🏆 20. / 55 Read more »
Discover the future of refrigeration and electronics at Bangkok RHVAC 2024 & Bangkok E&E 2024Thailand is now ready to stage Bangkok RHVAC 2024 and Bangkok E&E 2024, the largest trade show in Southeast Asia for refrigerators, air-conditioners, electrical and electronic products under this year’s theme “ONE STOP SOLUTION for NET ZERO Future” in Bangkok this September.
Source: manilabulletin - 🏆 25. / 51 Read more »
Source: TheManilaTimes - 🏆 2. / 92 Read more »
Source: TheManilaTimes - 🏆 2. / 92 Read more »